-
1.发明公开公开(公告)号：US20230212303A1
公开(公告)日：2023-07-06
申请号：US17822105
申请日：2022-08-24
申请人： Roche GlycArt AG
发明人： Pablo UMAÑA , Peter Brúnker , Claudia Ferrara Koller , Tobias Suter , Ursula Púntener , Ekkehard Móssner
IPC分类号： C07K16/28
CPC分类号： C07K16/2887 , C07K2317/24 , C07K2317/565
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
-
2.发明授权公开(公告)号：US11639397B2
公开(公告)日：2023-05-02
申请号：US14269950
申请日：2014-05-05
申请人： Roche Glycart AG
摘要： The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
-
公开(公告)号：US11365232B2
公开(公告)日：2022-06-21
申请号：US16783141
申请日：2020-02-05
申请人： Roche Glycart AG
发明人： Ralf Hosse , Christian Klein , Ekkehard Moessner , Laurence Bernard Peterson , Pablo Umana , Linda Wicker
摘要： The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
-
4.发明申请公开(公告)号：US20210002382A1
公开(公告)日：2021-01-07
申请号：US16787936
申请日：2020-02-11
申请人： Roche Glycart AG
发明人： Pablo UMAÑA , Peter BRÜNKER , Claudia FERRARA KOLLER , Tobias SUTER , Ursula PÜNTENER , Ekkehard MÖSSNER
摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
-
公开(公告)号：US10781258B2
公开(公告)日：2020-09-22
申请号：US16134494
申请日：2018-09-18
申请人： Roche Glycart AG
发明人： Marina Bacac , Thomas Hofer , Ralf Hosse , Christiane Neumann , Christian Klein , Ekkehard Moessner , Pablo Umana , Tina Weinzierl
摘要： The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
-
公开(公告)号：US20200172591A1
公开(公告)日：2020-06-04
申请号：US16783141
申请日：2020-02-05
申请人： Roche Glycart AG
发明人： Ralf Hosse , Christian Klein , Ekkehard Moessner , Laurence Bernard Peterson , Pablo Umana , Linda Wicker
摘要： The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
-
公开(公告)号：US10202464B2
公开(公告)日：2019-02-12
申请号：US15200507
申请日：2016-07-01
申请人： Roche Glycart AG
发明人： Oliver Ast , Peter Bruenker , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Pablo Umana
IPC分类号： C07K16/40 , C07K14/52 , C07K14/55 , A61K38/20 , A61K39/395 , C07K14/54 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/46 , A61K47/68 , A61K39/00
摘要： The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
-
公开(公告)号：US10184009B2
公开(公告)日：2019-01-22
申请号：US15849501
申请日：2017-12-20
申请人： Roche Glycart AG
发明人： Oliver Ast , Peter Bruenker , Anne Freimoser-Grundschober , Sylvia Herter , Thomas U. Hofer , Ralf Hosse , Christian Klein , Ekkehard Moessner , Valeria G. Nicolini , Pablo Umana
IPC分类号： C07K14/55 , A61K38/20 , C07K16/40 , C07K16/30 , C07K16/28 , A61K39/395 , A61K47/68 , A61K39/00
摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
-
公开(公告)号：US10106600B2
公开(公告)日：2018-10-23
申请号：US13070582
申请日：2011-03-24
申请人： Ulrich Brinkmann , Rebecca Croasdale , Harald Duerr , Christian Klein , Erhard Kopetzki , Wilma Lau , Joerg Thomas Regula , Juergen Michael Schanzer , Pablo Umana , Katharina Wartha
发明人： Ulrich Brinkmann , Rebecca Croasdale , Harald Duerr , Christian Klein , Erhard Kopetzki , Wilma Lau , Joerg Thomas Regula , Juergen Michael Schanzer , Pablo Umana , Katharina Wartha
摘要： The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
-
公开(公告)号：US10040843B2
公开(公告)日：2018-08-07
申请号：US15140414
申请日：2016-04-27
申请人： Roche Glycart AG
发明人： Lydia Jasmin Duerner , Thomas Emrich , Jens Fischer , Ralf Hosse , Ekkehard Moessner , Pablo Umana , Daigen Xu
摘要： The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
-
-
-
-
-
-
-
-
-
搜索结果
176 条记录 (耗时 0.045 秒)
